Lilly Launches TuneLab AI & ML Platform for Biotech Research

Today Eli Lilly and Company announced Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that enables biotech firms to access sophisticated models for drug discovery based on decades of Lilly data.

Lilly TuneLab's launch is an important milestone in democratizing high-value pharmaceutical innovation and gives smaller firms access to models that previously were only available to larger pharma companies. Lilly added that Lilly TuneLab's first release includes models trained on proprietary datasets worth $1 billion, including drug disposition, drug safety and preclinical data on hundreds of thousands of molecules.

Coming through Lilly TuneLab, biotech partners can benefit from Lilly's knowhow, contribute additional training data, and together iteratively improve the model for everyone's benefit.

Also Read: Advanced Formulation Technologies Streamlining Global Pharma Innovation

"Lilly has spent decades building comprehensive datasets for drug discovery. Today, we're sharing the intelligence gained from that investment to help lift the tide of biotechnology research," said Daniel Skovronsky, M.D., Ph.D., chief scientific officer, and president, Lilly Research Laboratories and Lilly Immunology. 

The platform utilizes federated learning technology, enabling companies to access Lilly's AI models without the risk of exposure to their proprietary data. Developed with global technology partners and artificial intelligence ("AI") experts, the platform will evolve with updates, including in vivo small molecule predictive models available exclusively in TuneLab.

Lilly TuneLab is the newest addition to the Lilly Catalyze360 platform, joining many other initiatives including Lilly Ventures, Gateway Labs, and ExploR&D. As Nisha Nanda, Ph.D., Senior Leader for Lilly Catalyze360 states, the goal of Catalyze360 is to build AI in drug discovery from a promise to effective leverage to help biotech innovators make a better decision about their odds of success.